A recent study confirms lenacapavir's effectiveness against HIV and highlights the capsid as a promising drug target despite resistance.

The tiny shell protecting the HIV virus resembles a slightly rounded ice cream cone, but there is nothing sweet about it. More than 40 million people worldwide live with AIDS because of this virus, ...

A novel bioengineering strategy utilizing peptide display technology on the AAV1 capsid has successfully generated ...

The FDA granted priority review, with a decision expected by June 19, 2025. LEN represents a novel class of HIV therapies by targeting the viral capsid, a multifunctional protein essential for HIV ...

From a virus's point of view, invading our cells is a matter of survival. The virus makes a living by highjacking cellular processes to produce more of the proteins that make it up. From our point of ...

Abselion, a pioneering life sciences technology company focused on simplifying biomolecule quantification, has expanded its product offering, with the launch of the AAVX Total Capsid Quantification ...

It’s crucial not to confuse viruses with bacteria, as viruses are infectious agents that can be pathogenic to the organisms ...